AIMEDBIO

• - AimedBio’s allergy disease therapeutic candidate P001 has been selected for the Korean Drug Development Fund (KDDF) “New Drug R&D Ecosystem Building” program, receiving funding over the next two years to support candidate optimization.
• - P001 is an immunotherapy antibody targeting an upstream receptor involved in inflammatory signaling, designed to treat allergic diseases driven by excessive immune responses.
• - The program is primarily focused on indications such as atopic dermatitis and chronic sinusitis, with potential for expansion into other allergic and autoimmune diseases.
  
  

Link: http://www.biospectator.com/view/news_view.php?varAtcId=19399